Natalizumab (NTZ) remains a widely used drug for the treatment of patients with highly active relapsing remitting multiple sclerosis (MS) due to its favourable efficacy profile on relapse rate, disability progression and magnetic resonance imaging (MRI) measures of disease activity. 1 Although generally well tolerated, the development of progressive multifocal leukoencephalopathy (PML), a rare but serious adverse effect of NTZ remains a concern among physicians and patients. PML is an often disabling and potentially fatal opportunistic infection of the central nervous system caused by the reactivation and pathogenic mutation of the JC polyomavirus in immunosuppressed individuals. 2 As of May 2016, the overall global incidence of NTZ-associated PML was 4.22 per 1000 patients (95% confidence interval (CI): 3.91-4.55 per 1000 patients). 3 We recognise that factors associated with an increased risk of NTZassociated PML include anti-JCV antibody positivity, prior use of immunosuppressive therapy and NTZ treatment duration of ⩾25 months. 4
Clinical vigilance remains the key method of identifying PML at the earliest symptomatic stage; however, this can be greatly enhanced with frequent MRI monitoring which offers the potential to identify emerging PML prior to the onset of clinical symptoms. The rationale for high-frequency MRI monitoring in NTZtreated patients with higher risk of PML was supported in a consensus guideline published in 2015 by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Study Group which recommended that NTZ-treated patients with MS who are at high risk of PML (JCV seropositive, treatment duration ⩾18 months) should have 3-4 monthly MRI brain screening using an MRI protocol that includes fluid-attenuated inversion recovery (FLAIR), T2-weighted and diffusion-weighted imaging (DWI) sequences. 5 Additional recommendations were proposed in a practical consensus guideline developed by a group of neurologists in Ireland and the United Kingdom; 2 this guideline further stratified patients based on serum JCV index positivity. Specifically, immunosuppressant-naive patients who are anti-JCV antibody-positive with an index ⩽1.5 hold a 1 in 885 risk of PML from 25 to 48 months of therapy and should have 6-monthly MRI scanning. Patients with an index ⩾1.5 hold a higher risk of PML (1 in 113) from 25 to 48 months of therapy and should have 3-4 monthly MRI scanning. Anti-JCV-positive patients with previous immunosuppression should be scanned 3-4 monthly. Hence, frequent MRI monitoring provides an option for JCV-positive patients to safely continue treatment with NTZ beyond 2 years by satisfying recommended pharmacovigilance criteria and allowing for a more individualised analysis of their risk. A review of the published asymptomatic cases suggested that an interval of 3-4 monthly MRI scans would have identified the majority of cases prior to symptom onset. 2 Clinical symptoms are not mandatory in the diagnosis of confirmed PML. A PML classification system has been proposed which allows the diagnosis of 'confirmed' (as opposed to suspected) PML based on the combination of compatible MRI findings and the presence of cerebrospinal fluid (CSF) JCV DNA. 6 This provides an alternative to the American Academy of Neurology (AAN) diagnostic criteria for PML, 7 which recommend that the presence of all three factors (compatible clinical features, compatible MRI findings and CSF JCV DNA) are necessary for a diagnosis of 'definite' PML which is not the case in several published asymptomatic NTZ-associated PML cases.
There is emerging evidence that patients who are asymptomatic at the time of PML diagnosis tend to have better outcomes. One retrospective analysis of 372 NTZ-associated PML cases showed that patients who remain asymptomatic at PML diagnosis had shorter average time to diagnosis (12 vs 28 days), more localised disease in the form of unilobar lesions (68% vs 37%), consistently lower disability scores over time and higher rates of survival (96.7% vs 75.4% after mean 12-month follow-up) compared to symptomatic patients. 1 It was argued, however, that the apparent longer duration of survival in asymptomatic patients may be biased by the short duration of follow-up, and that asymptomatic patients may represent a subgroup with inherently slower progression of PML and therefore further long-term validation of these findings is required. 1 Early diagnosis of PML is also believed to improve survival. Another study evaluated the disease course of 15 NTZ-associated PML patients managed at a specialist referral centre and demonstrated a survival rate of 100% within a median follow-up duration of 22 months. 8 This positive outcome was attributed to increased clinical vigilance leading to early diagnosis that allowed for the anticipation and timely provision of intensive care and optimisation of antiepileptic treatment where needed, especially when clinical worsening occurs with the onset of immune reconstitution inflammatory syndrome (IRIS) which frequently follows NTZ-associated PML, and also with uncontrolled seizure activity.
One obvious disadvantage of frequent MRI monitoring is the consumption of resources in relation to time, manpower and costing requirements for MRI scanning which may be difficult to justify in certain healthcare systems given the lack of formal risk-benefit analysis. This issue may be ameliorated by the recommendation that, at the very least, a limited MRI protocol involving T2, DWI and FLAIR sequences may be performed as part of the minimum requirement for safety monitoring, with a full MRI protocol including scanning the cervical and thoracic spine still only occurring annually to assess efficacy. 2 There have been reported cases of NTZ-associated PML in patients who were recently negative for CSF JCV DNA. 2 Both CSF JCV antibody positivity status and index values can fluctuate over time. 2 From a practical viewpoint, the process of sampling CSF and awaiting CSF JCV antibody test results are possibly less convenient and take longer than obtaining and interpreting an MRI scan. Also, the clinical presentation of PML is often insidious with the development of subtle behavioural and cognitive abnormalities occurring more frequently than other more clinically obvious neurological symptoms. 1 Recent studies have demonstrated highly characteristic and predictive MRI manifestations of asymptomatic NTZ-associated PML lesions. 9-11 These factors further support intensive MRI surveillance in NTZ-treated patients and emphasise the value of MRI as a powerful and reliable paraclinical tool in the diagnosis of PML. The evidence for frequent MRI scanning with an abbreviated protocol has now been accepted by the European Medicines Agency (EMA) and recommended in the latest guidance on pharmacovigilance with NTZ. 12 Concern has raised that more frequent brain MRI scans may generate PML queries if new MS lesions are identified, leading to unnecessary CSF sampling; however in the authors' experience, this is not the case given the efficacy of NTZ at suppressing MRI activity. If breakthrough MS lesions are identified, this may indicate treatment failure and allow a change in therapy at an earlier stage.
In conclusion, detection of patients with NTZassociated PML can be a diagnostic dilemma. Frequent MRI monitoring in NTZ-treated patients with higher risk of PML is highly applicable, useful and constitutes best clinical practice in the detection of PML given the available resources. The establishment of an in-hospital MRI surveillance system with abbreviated scanning protocols for NTZ-treated patients along with collaboration between the treating neurologist and neuroradiologist is strongly recommended to facilitate timely detection and intervention of such patients with view to optimising clinical outcomes.
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High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML -NO Christian Enzinger
Since its first implementation in the diagnostic criteria more than 15 years ago, based on scientific progress and paralleled by cumulative clinical confidence in its interpretation, magnetic resonance imaging (MRI) of the brain has gained an increasingly important, now firmly established, role in the diagnosis and differential diagnosis of multiple sclerosis (MS). 1 Moreover, MRI may also provide further information relevant for managing patients with MS concerning prognosis, treatment decisions, and, more recently, monitoring disease activity and efficacy of treatments. 2 Given these achievements and its high sensitivity, it is thus self-evident to also advocate a role for MRI in detecting side effects associated with a treatment, including opportunistic infections. Accordingly, in 2016, the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee updated recommendations to minimize the risk of the rare brain infection progressive multifocal leukoencephalopathy (PML) with natalizumab treatment in MS, suggesting to consider more frequent MRI scans for patients at higher risk. 3 While the author's position certainly is not to contradict this recommendation, it shall rather serve to also critically highlight potential drawbacks and practical challenges, both for radiologists and neurologists, implicated with such an approach.
However, before detailing concerns regarding reliable detection of asymptomatic PML in natalizumabtreated MS patients using high-frequency MRI, it appears insightful to first scrutinize the performance of established, scientifically validated, and formalized radiological criteria in easier situations. Given the wealth of knowledge on the morphology and pattern of distribution of MS lesions and the algorithms
